...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR 2019

Ok,,,,Bear,,like its not unlikely for me to get confussed here,,,,,,,hahha,,sorry for the obtuseness,,,,,,,,,,,so where does ZEN-3309 come in,,, I was of the impression that it would be used for breast cancer,,,,,,,or is it also administered with 3694 for this type of cancer. I had thought that ZEN-3694 was being focused on prostate.

And what ever happened to the Curate AI technology,,,,,,cured the advanced stage of prostate cancer with 3694,,,,,,,,,,,,,,,,,,,no updates or other from Zenith etc. Very odd imo.

Share
New Message
Please login to post a reply